

David A Boothman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1184882/publications.pdf>

Version: 2024-02-01

139
papers

11,228
citations

22099

59
h-index

30010

103
g-index

142
all docs

142
docs citations

142
times ranked

14856
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized Genome-Scale Metabolic Models Identify Targets of Redox Metabolism in Radiation-Resistant Tumors. <i>Cell Systems</i> , 2021, 12, 68-81.e11.	2.9	39
2	MTHFD2 Blockade Enhances the Efficacy of Î²-Lapachone Chemotherapy With Ionizing Radiation in Head and Neck Squamous Cell Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536377.	1.3	11
3	Targeting Base Excision Repair in Cancer: NQO1-Bioactivatable Drugs Improve Tumor Selectivity and Reduce Treatment Toxicity Through Radiosensitization of Human Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1575.	1.3	13
4	Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to Î²-lapachone. <i>Redox Biology</i> , 2020, 30, 101440.	3.9	31
5	NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. <i>Nature Communications</i> , 2019, 10, 3251.	5.8	55
6	Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1355-1365.	1.9	19
7	Targeting NAD+ Metabolism to Enhance Radiation Therapy Responses. <i>Seminars in Radiation Oncology</i> , 2019, 29, 6-15.	1.0	22
8	NQO1-dependent, Tumor-selective Radiosensitization of Nonâ€‘small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 2601-2609.	3.2	37
9	Modulators of Redox Metabolism in Head and Neck Cancer. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 1660-1690.	2.5	14
10	Genome-Scale Modeling of NADPH-Driven Î²-Lapachone Sensitization in Head and Neck Squamous Cell Carcinoma. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 937-952.	2.5	22
11	Phase 1 study of ARQ 761, a Î²-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis. <i>British Journal of Cancer</i> , 2018, 119, 928-936.	2.9	66
12	Following anticancer drug activity in cell lysates with DNA devices. <i>Biosensors and Bioelectronics</i> , 2018, 119, 1-9.	5.3	14
13	Kub5-Hera<i>RPRD1B</i> Deficiency Promotes â€œBRCAnessâ€‘and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 6459-6470.	3.2	11
14	Using a novel NQO1 bioactivatable drug, betaâ€‘lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 83-88.	0.8	24
15	Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors. <i>Biomaterials</i> , 2017, 118, 84-93.	5.7	60
16	The NQO1 bioactivatable drug, Î²-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. <i>Journal of Biological Chemistry</i> , 2017, 292, 18203-18216.	1.6	72
17	Phase 1 study of ARQ 761, a Î²-lapachone analog that promotes NQO1-mediated programmed cancer cell necrosis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2517-2517.	0.8	2
18	Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. <i>Cancer Cell</i> , 2016, 30, 940-952.	7.7	104

#	ARTICLE	IF	CITATIONS
19	Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant <i>KRAS</i> Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5851-5863.	3.2	67
20	NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1757-1767.	1.9	46
21	NQO1 Bioactivatable Drugs Enhance Radiation Responses. , 2016, , 225-252.		1
22	Lysosome-oriented, dual-stage pH-responsive polymeric micelles for Î²-lapachone delivery. <i>Journal of Materials Chemistry B</i> , 2016, 4, 7429-7440.	2.9	10
23	Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights. <i>European Journal of Medicinal Chemistry</i> , 2016, 122, 1-16.	2.6	65
24	Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC. <i>Molecular Cancer Research</i> , 2016, 14, 14-25.	1.5	50
25	The Kub5-Hera/RPRD1B interactome: a novel role in preserving genetic stability by regulating DNA mismatch repair. <i>Nucleic Acids Research</i> , 2016, 44, 1718-1731.	6.5	21
26	Using DNA devices to track anticancer drug activity. <i>Biosensors and Bioelectronics</i> , 2016, 80, 647-653.	5.3	10
27	Galactic cosmic ray simulation at the NASA Space Radiation Laboratory. <i>Life Sciences in Space Research</i> , 2016, 8, 38-51.	1.2	112
28	XRN2 Links Transcription Termination to DNA Damage and Replication Stress. <i>PLoS Genetics</i> , 2016, 12, e1006107.	1.5	88
29	Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways. <i>Clinical Pharmacology: Advances and Applications</i> , 2015, 7, 57.	0.8	12
30	Esterase-activatable Î²-lapachone prodrug micelles for NQO1-targeted lung cancer therapy. <i>Journal of Controlled Release</i> , 2015, 200, 201-211.	4.8	88
31	The cancer cell "energy grid": TGF-Î²1 signaling coordinates metabolism for migration. <i>Molecular and Cellular Oncology</i> , 2015, 2, e981994.	0.3	17
32	Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 534-541.	0.9	43
33	Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by Î²-lapachone. <i>Cancer & Metabolism</i> , 2015, 3, 12.	2.4	104
34	Nanotechnology-enabled delivery of NQO1 bioactivatable drugs. <i>Journal of Drug Targeting</i> , 2015, 23, 672-680.	2.1	26
35	Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 5058-5069.	0.4	33
36	Tumor-Selective, Futile Redox Cycle-Induced Bystander Effects Elicited by NQO1 Bioactivatable Radiosensitizing Drugs in Triple-Negative Breast Cancers. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 237-250.	2.5	37

#	ARTICLE	IF	CITATIONS
37	The Transcription Factor TFII-I Promotes DNA Translesion Synthesis and Genomic Stability. PLoS Genetics, 2014, 10, e1004419.	1.5	37
38	Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. Nature Communications, 2014, 5, 5811.	5.8	72
39	Prodrug Strategy to Achieve Lyophilizable, High Drug Loading Micelle Formulations Through Diester Derivatives of I ² Lapachone. Advanced Healthcare Materials, 2014, 3, 1210-1216.	3.9	27
40	Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair. Nucleic Acids Research, 2014, 42, 4996-5006.	6.5	36
41	Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases. Critical Reviews in Eukaryotic Gene Expression, 2014, 24, 15-28.	0.4	438
42	ATM Regulates Insulin-Like Growth Factor 1-Secretory Clusterin (IGF-1-sCLU) Expression that Protects Cells against Senescence. PLoS ONE, 2014, 9, e99983.	1.1	25
43	The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer Cells. Clinical Cancer Research, 2013, 19, 4740-4749.	3.2	61
44	Hemoglobin-Based Oxygen Carrier Mitigates Transfusion-Mediated Pancreas Cancer Progression. Annals of Surgical Oncology, 2013, 20, 2073-2077.	0.7	6
45	Cytoplasmic TRADD Confers a Worse Prognosis in Glioblastoma. Neoplasia, 2013, 15, 888-897.	2.3	16
46	Superparamagnetic Iron Oxide Nanoparticles: Amplifying ROS Stress to Improve Anticancer Drug Efficacy. Theranostics, 2013, 3, 116-126.	4.6	277
47	Catalase Abrogates I ² -Lapachone-Induced PARP1 Hyperactivation- Directed Programmed Necrosis in NQO1-Positive Breast Cancers. Molecular Cancer Therapeutics, 2013, 12, 2110-2120.	1.9	85
48	Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8088-8088.	0.8	2
49	Defective DNA Mismatch Repair-dependent c-Abl-p73-GADD45 [±] Expression Confers Cancer Chemoresistance. , 2012, , 191-210.		0
50	An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis. Cancer Research, 2012, 72, 3038-3047.	0.4	121
51	Klotho Inhibits Transforming Growth Factor- β 1 (TGF- β 1) Signaling and Suppresses Renal Fibrosis and Cancer Metastasis in Mice. Journal of Biological Chemistry, 2011, 286, 8655-8665.	1.6	453
52	Overcoming Endosomal Barrier by Amphotericin B-Loaded Dual pH-Responsive PDMA- <i>b</i> -PDPA Micelleplexes for siRNA Delivery. ACS Nano, 2011, 5, 9246-9255.	7.3	218
53	Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGF β 1 signaling to confer survival. Nature Precedings, 2011, , .	0.1	0
54	Nanosopic micelle delivery improves the photophysical properties and efficacy of photodynamic therapy of protoporphyrin IX. Journal of Controlled Release, 2011, 151, 271-277.	4.8	113

#	ARTICLE	IF	CITATIONS
55	Photoactivation switch from type II to type I reactions by electron-rich micelles for improved photodynamic therapy of cancer cells under hypoxia. <i>Journal of Controlled Release</i> , 2011, 156, 276-280.	4.8	202
56	Sporadic breast cancer patients' germline DNA exhibit an AT-rich microsatellite signature. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 275-283.	1.5	13
57	CRM1 Protein-mediated Regulation of Nuclear Clusterin (nCLU), an Ionizing Radiation-stimulated, Bax-dependent Pro-death Factor. <i>Journal of Biological Chemistry</i> , 2011, 286, 40083-40090.	1.6	32
58	Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of I^2 -Lapachone for Pancreatic Cancer Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 275-285.	3.2	96
59	Prostate Cancer Radiosensitization through Poly(ADP-Ribose) Polymerase-1 Hyperactivation. <i>Cancer Research</i> , 2010, 70, 8088-8096.	0.4	82
60	I^2 -Lapachone Micellar Nanotherapeutics for Non-Small Cell Lung Cancer Therapy. <i>Cancer Research</i> , 2010, 70, 3896-3904.	0.4	135
61	Loss of p15/Ink4b accompanies tumorigenesis triggered by complex DNA double-strand breaks. <i>Carcinogenesis</i> , 2010, 31, 1889-1896.	1.3	11
62	Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2485-2490.	3.3	215
63	TGF- β 1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. <i>Journal of Clinical Investigation</i> , 2010, 120, 290-302.	3.9	115
64	EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma. <i>Cancer Research</i> , 2009, 69, 4252-4259.	0.4	232
65	Intracellular Clusterin Inhibits Mitochondrial Apoptosis by Suppressing p53-Activating Stress Signals and Stabilizing the Cytosolic Ku70-Bax Protein Complex. <i>Clinical Cancer Research</i> , 2009, 15, 48-59.	3.2	142
66	The receptor interacting protein 1 mediates a link between NF- κ B and PI3-kinase signaling. <i>Cell Cycle</i> , 2009, 8, 2671-2672.	1.3	3
67	Intratumoral Delivery of I^2 -Lapachone via Polymer Implants for Prostate Cancer Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 131-139.	3.2	68
68	Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations. <i>Cancer Research</i> , 2009, 69, 7644-7652.	0.4	138
69	In vivo Off-Resonance Saturation Magnetic Resonance Imaging of I^2 -Targeted Superparamagnetic Nanoparticles. <i>Cancer Research</i> , 2009, 69, 1651-1658.	0.4	94
70	RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF- κ B-Mediated Inhibition of the mTOR-S6K-IRS1 Negative Feedback Loop and Down-regulation of PTEN. <i>Cancer Research</i> , 2009, 69, 4107-4111.	0.4	53
71	The Receptor Interacting Protein 1 Inhibits p53 Induction through NF- κ B Activation and Confers a Worse Prognosis in Glioblastoma. <i>Cancer Research</i> , 2009, 69, 2809-2816.	0.4	134
72	Vanadium-induced apoptosis of HaCaT cells is mediated by c-Fos and involves nuclear accumulation of clusterin. <i>FEBS Journal</i> , 2009, 276, 3784-3799.	2.2	28

#	ARTICLE	IF	CITATIONS
73	DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. <i>British Journal of Pharmacology</i> , 2009, 158, 679-692.	2.7	66
74	Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression. <i>Cell Cycle</i> , 2009, 8, 473-481.	1.3	41
75	Role of c-Abl Kinase in DNA Mismatch Repair-dependent G2 Cell Cycle Checkpoint Arrest Responses. <i>Journal of Biological Chemistry</i> , 2008, 283, 21382-21393.	1.6	27
76	DNA Mismatch Repair-dependent Activation of c-Abl/p73/GADD45-mediated Apoptosis. <i>Journal of Biological Chemistry</i> , 2008, 283, 21394-21403.	1.6	29
77	Stress-induced Premature Senescence (SIPS). <i>Journal of Radiation Research</i> , 2008, 49, 105-112.	0.8	105
78	Nonhomologous End Joining Is Essential for Cellular Resistance to the Novel Antitumor Agent, $\hat{\text{I}}^2$ -Lapachone. <i>Cancer Research</i> , 2007, 67, 6936-6945.	0.4	67
79	An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by $\hat{\text{I}}^2$ -lapachone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 11832-11837.	3.3	318
80	Secretory clusterin (sCLU) is a hallmark sensor of DNA damage, cell stress, and cellular senescence: Evidence for similar regulation of sCLU expression after cellular stress and replicative senescence. <i>International Congress Series</i> , 2007, 1299, 150-157.	0.2	1
81	Upregulation of NAD(P)H:Quinone Oxidoreductase By Radiation Potentiates the Effect of Bioreductive $\hat{\text{I}}^2$ -Lapachone on Cancer Cells. <i>Neoplasia</i> , 2007, 9, 634-642.	2.3	67
82	$\hat{\text{I}}^2$ -Lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. <i>Journal of Controlled Release</i> , 2007, 122, 365-374.	4.8	152
83	Multifunctional Polymeric Micelles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems. <i>Nano Letters</i> , 2006, 6, 2427-2430.	4.5	1,180
84	New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. <i>Journal of Molecular Histology</i> , 2006, 37, 203-218.	1.0	67
85	Mornings with art, lessons learned: Feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses. <i>Journal of Cellular Physiology</i> , 2006, 209, 604-610.	2.0	20
86	Modulating $\hat{\text{I}}^2$ -Lapachone release from polymer millirods through cyclodextrin complexation. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 2309-2319.	1.6	38
87	Calcium-dependent Modulation of Poly(ADP-ribose) Polymerase-1 Alters Cellular Metabolism and DNA Repair. <i>Journal of Biological Chemistry</i> , 2006, 281, 33684-33696.	1.6	113
88	Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. <i>International Journal of Nanomedicine</i> , 2006, 1, 155-162.	3.3	44
89	Susceptibility of cancer cells to $\hat{\text{I}}^2$ -lapachone is enhanced by ionizing radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 212-219.	0.4	55
90	Delayed Activation of Insulin-like Growth Factor-1 Receptor/Src/MAPK/Egr-1 Signaling Regulates Clusterin Expression, a Pro-survival Factor. <i>Journal of Biological Chemistry</i> , 2005, 280, 14212-14221.	1.6	141

#	ARTICLE	IF	CITATIONS
91	DNA Mismatch Repair-dependent Response to Fluoropyrimidine-generated Damage. <i>Journal of Biological Chemistry</i> , 2005, 280, 5516-5526.	1.6	108
92	Heat-Induced Up-Regulation of NAD(P)H:Quinone Oxidoreductase Potentiates Anticancer Effects of \hat{I}^2 -Lapachone. <i>Clinical Cancer Research</i> , 2005, 11, 8866-8871.	3.2	38
93	Development of \hat{I}^2 -Lapachone Prodrugs for Therapy Against Human Cancer Cells with Elevated NAD(P)H:Quinone Oxidoreductase 1 Levels. <i>Clinical Cancer Research</i> , 2005, 11, 3055-3064.	3.2	84
94	IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2004, 568, 97-110.	0.4	74
95	Role of DNA mismatch repair in apoptotic responses to therapeutic agents. <i>Environmental and Molecular Mutagenesis</i> , 2004, 44, 249-264.	0.9	52
96	A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies. <i>Lung Cancer</i> , 2004, 44, 111-119.	0.9	6
97	Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. <i>Pharmaceutical Research</i> , 2003, 20, 1626-1633.	1.7	126
98	Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. <i>Oncogene</i> , 2003, 22, 5813-5827.	2.6	226
99	A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. <i>Oncogene</i> , 2003, 22, 7376-7388.	2.6	57
100	Ku70 suppresses the apoptotic translocation of Bax to mitochondria. <i>Nature Cell Biology</i> , 2003, 5, 320-329.	4.6	329
101	Clusterin: a protein with multiple functions as a potential ionizing radiation exposure marker. <i>International Congress Series</i> , 2003, 1258, 219-232.	0.2	1
102	Synthesis and Functional Analyses of Nuclear Clusterin, a Cell Death Protein. <i>Journal of Biological Chemistry</i> , 2003, 278, 11590-11600.	1.6	344
103	$\hat{I}^2/4$ -Calpain Activation in \hat{I}^2 -Lapachone-Mediated Apoptosis. <i>Cancer Biology and Therapy</i> , 2003, 2, 141-152.	1.5	91
104	Repression of IR-Inducible Clusterin Expression by the p53 Tumor Suppressor Protein. <i>Cancer Biology and Therapy</i> , 2003, 2, 372-380.	1.5	90
105	Radiation Resistance. , 2002, , 1-11.		8
106	NAD(P)H:quinone oxidoreductase (NQO1) activity is the principal determinant of \hat{I}^2 -lapachone cytotoxicity.. <i>Journal of Biological Chemistry</i> , 2002, 277, 9622.	1.6	0
107	\hat{I}^2 -Lapachone-Induced Apoptosis in Human Prostate Cancer Cells: Involvement of NQO1/xip3. <i>Experimental Cell Research</i> , 2001, 267, 95-106.	1.2	115
108	When X-ray-inducible proteins meet DNA double strand break repair. <i>Seminars in Radiation Oncology</i> , 2001, 11, 352-372.	1.0	63

#	ARTICLE	IF	CITATIONS
109	Calpains and apoptosis. Korean Journal of Biological Sciences, 2001, 5, 267-274.	0.1	4
110	Calcium Is a Key Signaling Molecule in \hat{I}^2 -Lapachone-mediated Cell Death. Journal of Biological Chemistry, 2001, 276, 19150-19159.	1.6	143
111	Coordinate modulation of Sp1, NF $\hat{\kappa}$ B, and p53 in confluent human malignant melanoma cells after ionizing radiation. FASEB Journal, 2000, 14, 379-390.	0.2	73
112	NF $\hat{\kappa}$ B Activation by Camptothecin. Journal of Biological Chemistry, 2000, 275, 9501-9509.	1.6	139
113	Activation of a Cysteine Protease in MCF-7 and T47D Breast Cancer Cells during \hat{I}^2 -Lapachone-Mediated Apoptosis. Experimental Cell Research, 2000, 255, 144-155.	1.2	123
114	NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of \hat{I}^2 -Lapachone Cytotoxicity. Journal of Biological Chemistry, 2000, 275, 5416-5424.	1.6	335
115	The Dark Side of Estrogens. Trends in Endocrinology and Metabolism, 2000, 11, 443-444.	3.1	0
116	Cellular and Molecular Responses to Topoisomerase I Poisons: Exploiting Synergy for Improved Radiotherapy. Annals of the New York Academy of Sciences, 2000, 922, 274-292.	1.8	25
117	Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Research, 1999, 27, 2165-2174.	6.5	97
118	Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Therapy, 1999, 6, 155-162.	2.2	78
119	Niemann \hat{c} Pick Human Lymphoblasts Are Resistant to Phthalocyanine 4-Photodynamic Therapy-Induced Apoptosis. Biochemical and Biophysical Research Communications, 1999, 258, 506-512.	1.0	29
120	Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors. Journal of Neuro-Oncology, 1998, 37, 217-222.	1.4	49
121	DNA-Dependent Protein Kinase Does Not Play a Role in Adaptive Survival Responses to Ionizing Radiation. Environmental Health Perspectives, 1998, 106, 301.	2.8	3
122	Transcriptional Responses to Damage Created by Ionizing Radiation. , 1998, , 223-262.		0
123	Damage-Sensing mechanisms in human cells after ionizing radiation. Stem Cells, 1997, 15, 27-42.	1.4	12
124	Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors. International Journal of Radiation Oncology Biology Physics, 1996, 36, 369-376.	0.4	28
125	Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. International Journal of Radiation Oncology Biology Physics, 1996, 36, 361-368.	0.4	40
126	The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. Journal of Neuro-Oncology, 1996, 30, 1-6.	1.4	48

#	ARTICLE	IF	CITATIONS
127	2221 pRb alterations abrogate cell cycle control and increase apoptosis and radiosensitivity. International Journal of Radiation Oncology Biology Physics, 1996, 36, 385.	0.4	3
128	Enhanced expression of thymidine kinase in human cells following ionizing radiation. International Journal of Radiation Oncology Biology Physics, 1994, 30, 391-398.	0.4	56
129	Immediate X-Ray-Inducible Responses from Mammalian Cells. Radiation Research, 1994, 138, S44.	0.7	24
130	Alterations in Transcription Factor Binding in Radioresistant Human Melanoma Cells after Ionizing Radiation. Radiation Research, 1994, 138, S47.	0.7	42
131	Enhanced Malignant Transformation Is Accompanied by Increased Survival Recovery after Ionizing Radiation in Chinese Hamster Embryo Fibroblasts. Radiation Research, 1994, 138, S121.	0.7	11
132	Enhanced induction of tissue-type plasminogen activator in normal human cells compared to cancer-prone cells following ionizing radiation. International Journal of Radiation Oncology Biology Physics, 1992, 24, 949-957.	0.4	20
133	Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. International Journal of Radiation Oncology Biology Physics, 1992, 24, 939-948.	0.4	83
134	Effect of Caffeine on the Expression of a Major X-Ray-Induced Protein in Human Tumor Cells. Radiation Research, 1991, 125, 313.	0.7	18
135	Expression of the E. coli Lac Z gene from a defective HSV-1 vector in various human normal, cancer-prone and tumor cells. FEBS Letters, 1989, 258, 159-162.	1.3	16
136	Exploitation of elevated pyrimidine deaminating enzymes for selective chemotherapy. , 1989, 42, 65-88.		16
137	Anticarcinogenic potential of DNA-repair modulators. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1988, 202, 393-411.	0.4	40
138	Pharmacological Interference with DNA Repair. , 1987, , 431-436.		0
139	Analysis of 5-fluoro-2â€²-deoxycytidine and 5-trifluoromethyl-2â€²-deoxycytidine and their related antimetabolites by high-performance liquid chromatography. Biomedical Applications, 1986, 381, 343-355.	1.7	5